All Novartis articles – Page 2
-
ResearchConnections in flow
MIT’s Klavs Jensen tells us how his research ranges in size from a chip, to a fridge to a shipping container
-
BusinessCrispr goes commercial
Gene editing technique Crispr has shaken up genomics research and the commercial opportunities couldn’t be more evident
-
BusinessPharma kickback claims lead to individual prosecutions
Warner Chilcott and Novartis face large fines for paying doctors to prescribe their drugs
-
BusinessMerger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
Business
Novartis to buy experimental MS drug from GSK in $1bn deal
Deal will help to bolster Novartis’s pipeline for neurological disorder treatments
-
Opinion
Drugs in a class of their own
New drug types need careful regulation to reward innovation while protecting patients
-
FeaturePharma queues up for checkpoint inhibitor collaborations
Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits
-
Business
Injunction blocks first US biosimilar
Despite regulatory approval, Amgen is delaying sales of Sandoz’s version of filgrastim
-
Business
Novartis accused of ‘derailing’ trials for cheap eye disease drug
BMJ says pharma giant is trying to block access to a drug that would save the NHS millions
-
Business
US approves biosimilar filgrastim
Sandoz’s version of Amgen’s Neupogen is ‘biosimilar’ but not ‘interchangeable’
-
BusinessUS poised to approve its first ‘biosimilar’ drug
FDA panel recommends Sandoz’s copy of Amgen’s Neupogen
-
-
BusinessPharma vies to unleash immune system power on cancer
Immuno-oncological drugs look set to earn billions and significantly lengthen patients’ lives
-
Business
Drug companies rapped for anticompetitive behaviour
Italian authorities demand €1.2 billion in damages from Roche, Novartis and Pfizer
-
Business
Novartis enhances its focus with eyecare deal
Swiss firm buys rights to wet AMD drug from Ophthotech for up to $1bn
-
Business$25bn-plus trade sharpens pharma giants’ focus
Novartis’ asset swaps with GSK and Eli Lilly are the latest steps in an ongoing streamlining process
-
Business
Novartis and DSM trim jobs
Novartis to close US manufacturing site, both companies restructuring Swiss operations
-
Business
Novartis in the spotlight in mis-selling investigations
Crackdown on pharma marketing continues with US and Japanese cases
-
-
Business
Novartis sells off blood diagnostics division
$1.7bn deal reinforces firm’s focus on core pharmaceuticals
- Previous Page
- Page1
- Page2
- Page3
- Next Page